 |
|
|
| |
TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Co-infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir and Ribavirin
|
| |
| |
Reported by Jules Levin
AASLD Nov 7-11 2014 Boston
David Wyles1, Mark S Sulkowski2, Joseph J Eron3, Roger Trinh4, Jay Lalezari5, Jihad Slim6, Joseph Gathe7, Peter J Ruane8, Chia Wang9, Laveeza Bhatti 10, Richard Elion11, Fritz Bredeek12, Robert Brennan13, Gary Blick14,
Amit Khatri4, Krystal Gibbons4, Yiran B Hu4, Linda Fredrick4, Rakesh Tripathi4, Gretja Schnell4, Tami Pilot-Mati as4, Barbara Da Silva-Tillmann4, Barbara McGovern4, Andrew L Campbell4, Thomas Podsadecki4
1University of California San Diego, La Jolla, California, United States; 2Johns Hopkins University, Balti more, Maryland, United States; 3University of North Carolina, Chapel Hill, North Carolina, United States; 4AbbVie Inc., North Chicago, Illinois, United States; 5Quest Clinical Research, San Francisco, California, United States; 6St. Michael's Medical Center, Newark, New Jersey, United States; 7Cure C. Consorti um, Houston, Texas, United States; 8Peter J. Ruane, MD, Inc., Los Angeles, California, United States; 9Virginia Mason Medical Center, Seatt le, Washington, United States; 10AIDS Healthcare Foundati on, Los Angeles, California, United States; 11Whitman-Walker Health, Washington, DC, United States; 12Metropolis Medical Group, San Francisco, California, United States; 13Infectious Diseases Associates of Central Virginia, Lynchburg, Virginia, United States; 14CIRCLE CARE Center, Norwalk, Connecti cut, United States
|
| |
|
|
|
|
|
